Nucleic acids encoding antibodies against PD-1

US8088905B2 · kind B2 · utility

Assignees

• Wyeth, LLC · US
• MedImmune Limited · US

Inventors

• Mary Collins · Natick, US
• Clive Wood · Boston, US
• Beatriz Carreno · Clayton, US
• Deborah Luxenberg · Melrose, US
• Jason Jussif · Salem, US
• Laura Carter · Medford, US
• Frances K. Bennett · Melrose, US
• Viia Valge-Archer · Little Abington, GB
• John Andrews · Katy, US
• Caroline Russell · Cambridge, GB

Key dates

• Filing date: Mar 16, 2009
• Grant date: Jan 3, 2012
• Expiry date: Mar 16, 2029

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/76
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer, and other immune system disorders.